Results 301 to 310 of about 80,027 (384)

2024 ESC Guidelines for the management of elevated blood pressure and hypertension: what is new in pharmacotherapy? [PDF]

Eur Heart J Cardiovasc Pharmacother
McCarthy CP, Bruno RM, McEvoy JW, Touyz RM.   +3 more
europepmc   +1 more source

Angiotensin receptor antagonists to prevent sudden death in heart failure: does the dose matter? [PDF]

ISRN Cardiol, 2014
Francia P, Palano F, Tocci G, Adduci C, Ricotta A, Semprini L, Caprinozzi M, Balla C, Volpe M.   +8 more
europepmc   +1 more source

Antihypertensive effects of endothelin (ET) and angiotensin II ATi receptor antagonists in several types of hypertensive rats

, 2000
Rumi Nakao, Michihiro Saito, Takanori Ikeda, Hisashi Ohta, Megumu Okada, Peter K. S. Siegl, Masarn Nishikibe   +6 more
openalex   +1 more source

Investigating the efficacy of mineralocorticoid receptor antagonists for cardiovascular outcomes in different diseases

ESC Heart Failure, EarlyView.
Abstract Aims Mineralocorticoid receptor antagonists (MRAs) are crucial in managing cardiovascular diseases, with different MRAs demonstrating varying efficacy across diverse disease contexts. This research aims to compare the cardiovascular protective effects of different MRAs across various disease conditions.
Jiao Wang, Meijuan Zheng, Yuchun Yang, Lei Zhang, Muhuyati Wulasihan   +4 more
wiley   +1 more source

Spirit Interim Analysis: A Multicenter Prospective Observational Study of Outpatients with CKD and Decreased eGFR to Assess Therapeutic Algorithms, Disease Management and Quality of Life in Greece. [PDF]

J Clin Med
Petras D, Marinaki S, Panagoutsos S, Stefanidis I, Stylianou K, Ntounousi E, Lionaki S, Tzanakis I, Griveas I, Xidakis D, Theodoropoulou E, Gourlis D, Andreadellis A, Goumenos D, Liakopoulos V.   +14 more
europepmc   +1 more source

Effect of long-term treatment with L-158809, a novel angiotensin II receptor (ATjR) antagonist, on function of periaterial nerves in spontaneously hypertensive rats (SHR)

, 2000
Akira Nakatsuma, Hiromu Kawasaki, Yuji Kurosaki, Hiroaki Araki, Yutaka Gomita   +4 more
openalex   +1 more source

Quality of life in heart failure. The heart of the matter. A scientific statement of the Heart Failure Association and the European Association of Preventive Cardiology of the European Society of Cardiology

European Journal of Heart Failure, EarlyView.
For most patients with chronic, progressive illnesses, maintaining good quality of life (QoL), with preserved functional capacity, is just as crucial as prolonging survival. Patients with heart failure (HF) experience much worse QoL and effort intolerance than both the general population and people with other chronic conditions, since they present a ...
Maurizio Volterrani, Geza Halasz, Stamatis Adamopoulos, Pier Giuseppe Agostoni, Javed Butler, Andrew J.S. Coats, Alan Cohen‐Solal, Wolfram Doehner, Gerasimos Filippatos, Ewa Jankowska, Carolyn S.P. Lam, Ekaterini Lambrinou, Lars H. Lund, Giuseppe Rosano, Marco Metra, Stefania Paolillo, Pasquale Perrone Filardi, Amina Rakisheva, Gianluigi Savarese, Petar Seferovic, Carlo Gabriele Tocchetti, Massimo Piepoli   +21 more
wiley   +1 more source

Evaluation of the efficacy of angiotensin receptor-neprilysin inhibitor in patients with aortic stenosis undergoing transcatheter aortic valve implantation: protocol for a randomised, open-label, controlled study. [PDF]

BMJ Open
Kitahara H, Okita S, Sugawara T, Yaginuma H, Goto H, Yamamoto H, Kanda T, Matsuura K, Inaba Y, Hanaoka H, Matsumiya G, Kobayashi Y.   +11 more
europepmc   +1 more source

Angiotensin Coverting Enzyme Inhibitor (ACE-Inhibitor) vs. Angiotensin II type 1 Receptor Antagonist (AT1RA of AIIA)

, 2000
S. Sangwatananroj
openalex   +2 more sources